LAMMA study - Lung and Mesothelioma Study

• Research type

  Research Study

• Full title

  Identification of prognostic biomarkers and potential therapeutic targets in non-small-cell lung cancer and pleural mesothelioma

• IRAS ID

  223835

• Contact name

  Mohamad Nidal Bittar

• Contact email

  Mr.bittar@bfwhospitals.nhs.uk

• Sponsor organisation

  Salford University

• Duration of Study in the UK

  2 years, 0 months, 1 days

• Research summary

  Lung cancer (LC) is one of the most common cancer types in men and women. LC is the leading cause of cancer related deaths. In 2012, 1.8 million new cases of lung cancer were diagnosed worldwide and 1.6 million of these patients lost their lives. Therefore, even when compared to other cancer types, lung cancer has one of the largest mortality/incidence rates. This is primarily because the disease is diagnosed late in its course. 90% of diagnosed LC patients lose their lives within 5 years. Even though early diagnosis can increase the life span of the patients, current LC diagnosis methods are insufficient for early diagnosis.
  Malignant Pleural Mesothelioma (MPM) is an aggressive cancer mostly related to asbestos exposure, affecting 2,570 patients every year in the UK and approximately 20,000 worldwide. Due to the persistent exposure in many countries a worldwide progressive rise in MPM incidence is expected during the coming decades. Currently, there are no effective treatments for MPM andthe prognosis of patients is invariably poor. Moreover, modern targeted therapies that have shown benefit in other human tumours, including lung cancer, have failed in MPM. This has led to MPM being listed an “orphan disease” by the EU. Slides/paraffin embedded samples /clinical data obtained from lung cancer and mesothelioma patients will be needed to be analysed by panel of antibodies to determine immune checkpoint protein expression, apoptotic pathway, energy metabolism and invasiveness. IHC slides from 200 lung and 100 mesothelioma patients are required.

  The expected duration of the study is 2 years.

• REC name

  London - Queen Square Research Ethics Committee

• REC reference

  17/LO/2139

• Date of REC Opinion

  20 Dec 2017

• REC opinion

  Favourable Opinion